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Abstract 
Background: Diffuse infiltrative low-grade 
gliomas (LGG) of the cerebral hemispheres 
in the adult are tumors with distinct 
clinical, histological and molecular 
characteristics. WHO (World Health 
Organization) classification recognizes 
grade II astrocytomas, oligodendrogliomas 
and oligoastrocytomas. Conventional MRI 
is used for differential diagnosis, guiding 
surgery, planning radiotherapy and 
monitoring treatment response. 
Advanced imaging techniques are 
increasing the diagnostic accuracy. Low-
grade gliomas have been documented to 
undergo transformation into high-grade 
gliomas, and the time interval of this 
transformation has been reported to 
generally occur within 5 years in about 50% 
of patients diagnosed with low-grade 
gliomas.  
Methods: We have reviewed all adult 
patients operated on for hemispheric 
glioblastoma  at N Oblu Hospital in Iasi  
between 2006 and 2009 and in particular 
those patients with secondary glioblastoma. 
Results: from the total 110 cases of 
glioblastoma, ten of them were secondary 
to malignant transformation of an 
previously operated low grade glioma. Of 
the 10 patients with secondary 
glioblastoma, the initial histology was: gr II 
astocytoma in 6 cases, oligoastocytoma in 2 
cases and in oligodendroglioma in 2 cases. 
The mean patient age was 46.1± 0.9 years 
and the most frequent symptom was 
represented by seizures 70%, the mean time 
from the first symptom to diagnosis was 
11,2 months. 40% of the cases had subtotal 
resection and 60% had total resection 
(defined by the surgeon at the time of 
operation). 5 patients received radiotherapy 
postoperatively, 2 received both radio and 
chemotherapy and 3 had no adjuvant 
treatment. In our series the median time to 
malignant transformation was 32,5 months. 
Conclusions: Younger age, normal 
neurological examination and 
oligodendroglial histology are favorable 
prognostic factors, total/near total resection 
can improve seizure control, progression-
free and overall survival, mean while 
reducing the risk of malignant 
transformation. Early post-operative 
radiotherapy improves progression free but 
not overall survival. Chemotherapy can be 
useful both at recurrence after radiotherapy 
and as initial treatment after surgery to 
delay the risk of late neurotoxicity from 
large-field radiotherapy. 
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Low-grade gliomas are primary brain 
tumors classified as Grade I and II by the 
WHO grading system (14, 27) and occur 
primarily in children and young adults. The 
most common LGGs are the WHO Grade I 
pilocytic astrocytomas and the WHO Grade 
II diffuse astrocytomas (include fibrillary, 
gemistocytic and protoplasmic variants), 
oligodendrogliomas, and mixed 
oligoastrocytomas. It is important to 
separate gemistocytic astrocytoma, because 
it is more prone to malignant progression 
Patients with low-grade gliomas have a 
more favorable prognosis than patients with 
high grade glioma The median survival for 
patients with low-grade gliomas is between 
5 and 10 years (6, 9, 10, 13, 19) compared 
with a survival of only 14 months in 
patients with malignant glioma (GBM) 
(28). Despite this more favorable prognosis, 
patients with LGGs may survive for up to 
20 years, in 50–75% of patients with low-
grade gliomas the tumors grow 
continuously  and tend to progress to a 
higher grade, leading to neurological 
disability and ultimately to death (8, 24) In 
adults there are numerous prognostic 
factors reported in various prospective 
studies that have been shown to affect 
survival in patients with LGG, the most 
consistent are histological type, patient age, 
extent of resection (using postoperatively 
MRI imaging), and tumor size. Pilocytic 
astrocytomas, regardless of site (cerebral 
hemispheres, cerebellum, or spinal cord), 
are associated with a 10-year patient 
survival rate of ~ 80%, (6, 11, 14) but the 
rate is 100% in the subset of patients with 
brain tumors who undergo GTR. (3, 22) 
Within the diffuse LGG group there is a 
significant difference in patient outcome 
based on histological tumor type. 
The factors consistently shown to be 
associated with improved survival8 for 
patients with gliomas are younger age, (13, 
23) higher KPS scores, (18) 
oligodendroglioma pathology, (17) 
postoperative radiation therapy, (25) and 
GTR. (1, 15, 26)  
 The only factors that have been 
consistently shown to be associated with 
tumor recurrence (8) or malignant 
degeneration are preoperative contrast 
enhancement, (11, 12) tumor size, (1, 11) 
and STR. (1, 3) 
Methods  
We have analised all the patients 
operated on at 3rd Neurosurgical 
Department in N Oblu Hospital  for 
malignant glioma between 2006 and 2009 
and from the total of 110 cases ten percent 
of the malignant glioma were secondary to a 
malignant transformation of a low grade 
glioma. Our point of interest was 
represented by the patients with initial 
diagnostic of low grade gliomas.. Patients ≥ 
18 years old with tissue-proven diagnosis of 
a hemispheric WHO Grade I or II glioma 
(FA, oligodendroglioma, or mixed glioma) 
(14) at the initial diagnosis, supratentorial 
tumor location and adequate (> 6 months) 
clinical follow-up and imaging reports were 
included in the study. 
  Patients with, WHO Grade III or IV 
glioma including anaplastic astrocytoma, 
glioblastoma multiforme, anaplastic 
oligodendroglioma, or anaplastic mixed 
oligoastrocytoma at the initial operation; 
nonsupratentorial tumor location including 
optic chiasm, optic nerve(s), pons, medulla, 
cerebellum, or spinal cord; prior 
malignancy unless disease free ≥ 5 years 








  The clinical, operative, and hospital 
course records were reviewed. Information 
collected from clinical notes included 
patient demographics, age, presenting 
symptoms and signs, the interval between 
the first symptom and diagnostic, pre- and 
postoperative neuroimaging, extent of 
resection, postoperative neurological 
function, adjuvant therapy (radiotherapy 
and chemotherapy)medication history such 
as steroids and anticonvulsants. 
Preoperative MR images, including T1-
weighted images with and without contrast 
enhancement as well as T2-weighted 
images (and FLAIR images when available), 
were required. The preoperative tumor 
presence or absence of contrast 
enhancement was recorded. Perioperative 
death was defined as death within 30 days 
of surgery. 
  Tumor recurrence was defined as any 
definitive evidence of tumor recurrence or 
progressive growth on MR imaging as per 
the neuroradiology reports. Malignant 
degeneration was defined as either a notable 
increase in tumor contrast enhancement 
and/or a histopathologically proven 
malignant degeneration in tissue acquired 
during biopsy or resection (WHO Grade III 
or IV).  
Results  
From all of low grade gliomas operated 
on between 2006 – 2009 ten of them have 
suffered malignant transformation. All the 
patients have underwent primary and 
secondary resection, 60 percent of the cases 
were secondary to grade II astrocytomas 
(diffuse astrocytoma), 20 percent were 
secondary to oligodendroglioma and 
another 20 percent were secondary to 
oligoastrocytoma. The mean patient age 
was 46.1± 0.9 years, and 8 (80%) patients 
were male. The initial symptom was 
represented by seizures in 7 cases followed 
by motor impairment in 2 cases and rise 
intracranial hypertension in 1 case. The 
mean time from the initial symptom to 
diagnosis was 11.2±1.6 months. In our 
series 80% of the tumors were limited to a 
single cerebral lobe and in 20% there were 
involved 2 lobes, the most frequent affected 
lobe was the frontal lobe (6 cases) followed 
by the parietal lobe (5 cases). All of our 
cases had involvement of functional 
structures , in 6 cases there were functional 
areas involved, 2 cases involved the bazal 
ganglia and  another 2 cases involved 
vascular structures (cavernous sinus, carotid 
artery). As treatment 4 patients had subtotal 
surgical resection and 6 total resection (as 
defined by the neurosurgeon at the time of 
surgery) . The main complication was 
represented by hematoma in the tumoral 
bed wich was observed in 30% of the cases. 
50% had radiotherapy postoperatively 20% 
had both radio and chemotherapy while 
30% recived non of them. The median time 
to malignant transformation in our series 
was 32.5 months. (Figure 1 and Table 1) 
 
 









Characteristics of malignant transformed low grade gliomas series 
 Case 1 Case 2 Case 3 Case 4 Case  5 Case  6 Case 7 Case 8 Case9 Case 10 
Sex M M M F M M M M M F 
Age 42 41 37 55 59 45 60 39 50 33 












T To Dg 
(Months) 
2 36 30 1 2 2 10 3 `2 1 
Loc F FTP F P P P F FTI P FTI 
Funct 
Areas 
- 1 1 1 1 - 1 - 1 - 
Bazal 
Ganglia 
- 1 - - - - - 1 - - 
Vascular 
Srtucture 
- - - - - - - 1 - 1 
Biopsy  - - - - - - - - - - 
Str - 1 - 1 1 - - 1 - - 
Gtr 1 - 1 - - 1 1 - 1 1 

































Rxt 1 - - - 1 - 1 1 - 1 
Rtx+Cht - 1 - - - - - - 1 - 




52 29 28 23 84 40 16 54 36 21 
Pfs 
(Months) 




GBM GBM GBM GBM GBM GBM GBM GBM GBM GBM 
 
Mo- months, F-frontal, P-parietal, T-temporal, I-insular, GBM-glioblastoma multiforme, PFS- progression free 
survival, Dg AP- anatomopathological exam, T to DG-time to diagnosis, RXT-radiotherapy, CHT-
chemotherapy, STR-subtotal resection, GTR-gross total resection 
 
Next we will present two eloquent cases 
from our series: 
Case I 33 y o female presented for 
seizures for about 6 months, the MRI scan 
(Figure 2a) show a hipointense FTP lesion 
without contrast enhancement, she was 
operated using a pterional approach with 
subtotal resection, and the 
anatomopathological result was gr II 








radiotherapy and she had 6 cure of LINAC. 
At 9 months the patient was asymptomatic 
and the MRI study show a stabile lesion 
with no signs of progression or contrast 
enhancement (Figure 2b), the same aspect 
is observed at 21 months postoperatively 
(Figure 2c). At 22 months postop she came 
for right brachial monoparesis and 
depression the MRI scan show 2 areas of 
contrast enhancement (Figure 2d) and 
programmed for a PET scan wich was 
performed 1 month later wich show an 
hipermatabolic are in the right temporal 
pole (Figure 2e). She went for a second 
surgery with subtotal resection of the lesion 
and the anatomopathological result was 
glioblastoma multiforme. Postop the 
patient had a difficult evolution and the CT 
scan 1 month later showed a multicentric 
localization with involvement of both 
cerebral hemispheres (Figure 2 g-h). 
Case II 42 y old male presented for 
seizures for over 2 months and rised ICP 
syndrome, the CT scan with contrast 
enhancement show the lesion without 
contrast enhancement in the left frontal 
pole (Figure 3a), the patient was operated 
on (GTR) and the histology was gr II 
astrocytoma, he went for radiation therapy 
(6 cure of LINAC), at 4 months the patient 
was asymptomatic and the MRI exam show 
no signs of recurrence (Figure 3b), at 12 
months the patient had no neurological 
impairment and the MRI show a stable 
aspect with a hyperintense lesion in T2 in 
the left frontal pole (Figure 3c)  (scar 
secondary to surgery and radiotherapy) and 
we decided to go for surveillance and the 
MRI at 30 months postoperatively show no 
signs of progression or recurrence, same 
aspect as previous MRI exam) (Figure 3d).
 
 
Figure 2  A. Axial T1- weighted contrast enhanced MRI image show FTP area of hiposignal without contrast 
enhancement, B. and C. Images obtained 9 and 21 months later at the same patient after surgery and 6 cure of 
LINAC stable images, D. axial MRI images at 22 months are sowing 2 areas of contrast enhancement which 
weren’t present on the previous exam, E. PET scan is showing an area of hipermetabolism in the right temporal 
lobe and F. the correspondent images on T1-weighted with contrast enhanced MRI image G. and H. at 23 









Figure 3  A. Computer tomography with contrast enhancement show a izointense lesion without contrast 
enhancement without mass effect and surrounded by edema, B. MRI T2 axial image hyperintense area in the 
left frontal lobe at 4 months postoperatively and after radiotherapy, C. MRI exam at 12 months T2 axial shows a 
stable hyperintense lesion in the left frontal pole surrounded by minimum edema (arrow), D. T2 axial at 30 
months the lesion is stable with disappearance of edema, E. MRI exam at 52 months T1 with contrast 
enhancement show a hypointense lesion (thick arrow) in the left frontal pole and a thin rim of contrast 
enhancement (thin arrow) 
 
But at 56 months the patient presented 
for memory impairment, the MRI exam 
with contrast enhancement (Figure 3e) 
showed in T1 a hypointense lesion located 
within 2 cm from the previous tumoral bed 
with a thin rim of contrast enhancement 
without perilesional edema, we decided for 
reintervention and the patient was operated 
on using the old approach with gross total 
removal appreciated by the surgeon at the 
time, the histology this time was 
glioblastoma multiforme and he was sent to 
the oncology clinic for chemotherapy 
(temozolamide) and further surveillance. 
Discussion  
 The annual incidence of low grade 
glioma is about 4700 cases per year (27), 
which makes them onethird as common as 
their higher grade counterparts.4 This 
relatively low incidence has prevented the 
development of standardized treatment 
protocols. (2, 22) Treatment may include 
surveillance, biopsy, surgery, radiotherapy, 
or chemotherapy, and varies among 
different centers, location, and clinical 
presentation. (22) The majority of these 
tumors undergo recurrence or malignant 
transformation over time. The results vary 
among different studies with a 5 - year 
progression from 50 to 70% - and 
malignancy-free survival rates from 30 to 
70%. (6, 13, 17, 18, 25)  
Some patients have tumors that remain 
indolent for a couple of  years, in our study 
only one patient had a PFS of 84 months, 
whereas others rapidly recur and progress 
leading to neurological deterioration and 
subsequent death. This heterogeneity in 
patient evolution has led to the necessity of 
identification of certain factors associated 
with survival, recurrence, and malignant 
development for patients undergoing 
resection of a low-grade glioma. 
 The factors consistently known to be 
associated with improved survival include: 
1. younger age (patients < 40 years) (13, 
23). In our series 3 patients were younger 
than 40 years but  they didn’t had a better 
prognostic than the group of patients older 
than 40 years this is due the fact that we had 
a small and non-homogenous series. 
2. higher KPS score, (18)  
3. oligodendroglioma pathology,  
patients with FAs and oligodendrogliomas 
have similar rates of recurrence and/or 
progression although patients with FAs had 








grade tumors than patients with 
oligodendrogliomas, this may be due to the 
fact that FAs are primarily composed of 
aberrant astrocytes, which have a greater 
tendency to undergo malignant 
degeneration (17, 27)  
4. postoperative radiation therapy, (25) 
Although improved PFS was demonstrated 
for patients treated with immediate RT, this 
did not translate into improved OS. Besides 
prolonging the time to tumor progression, 
RT has several other potential benefits, 
such as symptom control, particularly 
epileptic seizures (27). In our series 5 
patient received radiotherapy and another 2 
received both radio and chemotherapy but 
with no impact among PFS and 
 5. GTR (< 1 cm residual tumor), The 
first report of outcome based on an MR 
imaging based assessment of surgical 
resection for LGG was reported by Berger 
et al. (1) in a series of 53 patients from the 
University of Washington. The extent of 
resection (based on the volume of residual 
disease) and tumor size were inversely 
correlated with the likelihood of tumor 
recurrence, time to recurrence, and tumor 
grade at the time of recurrence, recent 
studies have shown that gross total 
resection independently decrease the risk of 
malignant transformation, that suggest that 
GTR should be pursued when these 
tumors are amenable to radical resection. 
(1, 8, 15, 26) A critical point is a precise 
definition of total resection that for LGGs 
that do not enhance implies removal of all 
the hyperintense regions on T2 or FLAIR 
images and thus can only be determined by 
comparing preoperative and post-operative 
tumor volumes on MRI, respecting this 
standard even with intraoperative MRI-
guided surgery, total resection is achieved 
in no more than 36% of patients (24). GTR 
was achieved in 6 cases of our series but it 
was appreciated by the surgeon, without an 
immediate postoperatively MRI to confirm 
the extent of resection and these may also 
explain the short period until malignant 
transformation, comparatively with the data 
existing in the literature. 
The only factors that have been 
consistently shown to be associated with 
tumor recurrence or malignant 
degeneration are: 
1. preoperative contrast enhancement, 
(8, 11, 12, 27) which occurs where the 
blood-brain barrier is disturbed primarily in 
tumor areas, (2, 3) Contrast enhancement 
imaging often suggests a high-grade glioma, 
but it can also be present in 15–40% of 
patients with low grade gliomas. (7, 11, 23) 
The prognostic implications of contrast 
enhancement have been controversial and 
primarily limited to survival studies. (11, 
14, 16, 17, 20) Studies on contrast 
enhancement and recurrence remain 
relatively unknown and understudied. (17, 
29) contrast-enhancing low-grade gliomas 
may behave more like their higher grade, 
contrast-enhancing counterparts, which 
means that they are more likely to recur 
following resection. These tumors may 
therefore benefit from more aggressive 
and/or earlier use of adjuvant therapies. 
2. tumor size, the risk of recurrence 
increases 1.3 times for each centimeter 
increase in size and is independent of the 
extent of resection, tumor sizes ≥ 3 cm 
have the greatest statistical significance, 
with a 3.5 - fold increased risk of tumor 
recurrence. Larger low-grade gliomas, like 
malignant gliomas, (21) may have more 
microsatellite lesions and individual cell 
invasion, as well as more residual cells 
following resection, as a consequence of 








factors may not only predispose to tumor 
recurrence, but suggest that earlier 
treatment while the tumor is smaller will 
delay recurrence, presumably by decreasing 
the number of invading and/or residual 
cells that escape the tumor mass, which 
may eventually transform to a malignant 
phenotype,  
3.  STR. (1, 3) and  
4. molecular abnormalities (27) James L. 
Frazier reported in 2009 2 cases of rapid 
malignant transformation (12 weeks) in 
patients operated on for low grade 
astrocytomas , which didn’t enhance on the 
initial MRI and confirmed by 
anatomopathological exam and 
imunohistochemestry low value of  ki 76, 
but both cases had,  overexpresion of 
EDGF and absence of p53 mutation, 
molecular abnormalities seen in primary 
glioblastomas which may suggest possible 
risk factors for rapid malignant 
transformation.  
Current recommendations according to 
guidelines on management of low-grade 
gliomas elaborated by EFNS: European 
Federation of Neurological Societies and 
EANO: European Association for Neuro-
Oncology and published in European 
Journal of Neurology June 2010 27 are: 
“• Astrocytomas, oligodendrogliomas 
and oligoastrocytomas are diagnosed using 
morphological criteria according to WHO 
classification (Level A). 
• Combined loss of 1p/19q is a marker 
in favor of the diagnosis of 
oligodendroglioma or oligoastrocytoma 
(Level B). 
• MRI with contrast enhancement is the 
gold standard to monitor LGG after 
surgery: an MRI examination every 6 
months might be enough, unless the 
physicians think otherwise (good practice 
point). 
• MRS is useful for the differentiation 
of LGG from non-tumoral lesions, pre-
operative definition of extent and guiding 
stereotactic biopsies (Level C). 
• DSC-MRI can be employed in the 
follow-up to predict malignant 
transformation (Level C). 
• PET with FDG is useful for detecting 
malignant transformation in astrocytomas 
(Level C) and for differentiation between 
radiation necrosis and tumor recurrence 
(Level B) 
• PET with MET is useful for 
differentiation of LGG from non-tumoral 
lesions (Level B), guiding stereotactic biopsies 
(Level B), pre-treatment evaluation (Level B) 
and monitoring treatment (Level C). 
• Prophylactic AEDs must not be used 
before any epileptic seizures have occurred 
(Level A). 
• AEDs should be started after the first 
seizure (Level A). AEDs should be 
individualized according to seizure type, 
comedication, comorbidity and patient 
preferences (good practice point). 
• In patients who need a treatment with 
chemotherapeutics, non-EIAEDs are to be 
preferred (Level B). 
• Surgical resection represents the first 
treatment option, with the goal to 
maximally resect the tumor mass whenever 
possible, whilst minimizing the 
postoperative morbidity (Level B). 
• The identification of the eloquent 
cerebral areas, which have to be preserved 
during surgery, is performed through pre-
operative neuroimaging modalities 
(functional MRI, fiber tracking) and 
intraoperative brain mapping techniques 
(Level B), and awake surgery could 








• When surgery is not feasible (because 
of tumor location, extension or 
comorbidities), a biopsy (either stereotactic 
or open) should be performed to obtain a 
histological diagnosis (good practice point). 
• For patients with unfavorable 
prognostic factors (older age, incomplete or 
no resection, existing neurological 
symptoms), an adjuvant treatment is 
indicated at any time (Level B), and this is 
more commonly RT (good practice point). 
• A total RT dose of 50.4–54 Gy in 
fractions of 1.8 Gy represents the current 
standard of care (Level A). 
Modern RT techniques (conformal dose 
delivery or intensity modulated techniques) 
should preferably be used (Level B). 
• Younger patients (<40 years of age) 
with (nearly) complete resection and 
tumors with an oligodendroglial 
component have a more favorable 
prognosis and can be observed after surgery 
(Level B), but close follow-up is needed 
(good practice point). 
• Chemotherapy is an option for 
patients with recurrence after surgery and 
radiation therapy (Level B). 
• Chemotherapy is an option as initial 
treatment for patients with large residual 
tumors after surgery or unresectable tumors 
to delay the risk of late neurotoxicity from 
large-field RT, especially when 1p/19q loss 
is present (Level B). 
• Neuropsychological tests, at diagnosis 
and during the follow-up, can be useful, 
being selected according to the needs of the 
clinical setting (good practice point). The 
neuropsychological tests must have 
standardized materials and administration 
procedures, published normative data, 
moderate to high test–retest reliability, brief 
administration time (30 – 40 min) and be 
suitable to monitor changes over time 
(good practice point). 
• Cognitive rehabilitation can be helpful 
(Level B)” 
Conclusions 
Patients with low-grade gliomas have a 
more favorable prognosis than patients with 
high grade glioma. Despite this, the 
majority of patients with low-grade gliomas 
suffer either tumor progression or 
degeneration into to a more malignant 
lession (8) in our series the median to 
malignant transformation was 32,5 months 
which is comparable with the data existing 
in the literature (32 months (8)). 
Younger age, normal neurological 
examination, oligodendroglial histology and 
1p loss (we don’t have the possibility to 
evaluate molecular markers) are favorable 
prognostic factors.  
Early post-operative radiotherapy 
improves progression free survival but not 
overall survival. Chemotherapy can be 
useful as initial treatment after surgery or  
at recurrence after radiotherapy. 
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